Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia

Completed · Phase 4 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The study aims to assess the effects of single dose and repeated weekly dosing of 50mg d-cycloserine versus placebo on cognitive and memory functioning in schizophrenia patients. The study will also examine the effects of 50mg d-cycloserine on positive symptoms and negative symptoms, as well as assess tolerability and side-effects.

Key facts

Study ID

NCT00455702

Run by

Massachusetts General Hospital

People needed

38

Starts

2004-07-01

Expected to finish

2007-04-01

Last updated by the study team

2014-08-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female
• Age 18-65 years
• Diagnosis of schizophrenia or schizoaffective disorder, depressed type
• Stable dose of antipsychotic for at least 4 weeks.
• Able to provide informed consent
• Able to complete a cognitive battery

You may not qualify if…

• Current treatment with clozapine
• Dementia
• Seizure disorder
• Unstable medical illness
• Active substance abuse
• Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.